Q1 Earnings Forecast for BDTX Issued By HC Wainwright

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for Black Diamond Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.26) EPS and FY2027 earnings at ($0.96) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a report on Thursday. BTIG Research upped their price objective on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group reissued a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday. Finally, Wall Street Zen cut Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.83.

Black Diamond Therapeutics Stock Up 7.3%

Shares of BDTX stock opened at $1.92 on Friday. Black Diamond Therapeutics has a 52-week low of $1.60 and a 52-week high of $4.94. The stock has a market cap of $110.02 million, a PE ratio of -2.56 and a beta of 3.28. The business has a 50-day simple moving average of $1.84 and a 200-day simple moving average of $2.27.

Institutional Investors Weigh In On Black Diamond Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership increased its stake in shares of Black Diamond Therapeutics by 549.2% during the third quarter. Arrowstreet Capital Limited Partnership now owns 896,853 shares of the company’s stock worth $3,399,000 after purchasing an additional 758,709 shares in the last quarter. Marshall Wace LLP purchased a new position in Black Diamond Therapeutics in the 2nd quarter valued at about $1,830,000. Renaissance Technologies LLC lifted its stake in Black Diamond Therapeutics by 73.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,643,747 shares of the company’s stock valued at $3,501,000 after buying an additional 694,012 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Black Diamond Therapeutics by 51.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,301,664 shares of the company’s stock worth $2,772,000 after buying an additional 444,649 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Black Diamond Therapeutics in the 4th quarter worth about $1,024,000. Institutional investors and hedge funds own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.